Sanofi-Aventis said that Switzerland''s regulatory body Swissmedic has approved anti-obesity drug Acomplia for sale in the country.


Sanofi-Aventis said the regulator has authorised the use of the drug for "for obese patients (Body Mass Index - BMI - greater than or equal to 30 kg/m2) or for overweight patients (BMI greater than or equal to 27 kg/m2) with at least one associated cardiovascular risk factor, after insufficient weight reduction following physical activity or alimentary adaptation.



Physicians in Switzerland may prescribe the 20 mg once-daily acomplia pill along with a light diet and physical activity for obese or overweight patients with at least one associated cardiovascular risk factor and after insufficient weight reduction following physical activity or food adaptation.